Immunis Treats its First Patients for Sarcopenic Obesity Immunis, Inc , a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, announces that it has initiated treatment in several patients of its STEM-META Phase 2 clinical trial
Immunis Closes $25 Million Series A-1 Financing Round Immunis, Inc , a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 clinical trials
Immunis Announces Secretome Product for Muscle Atrophy The goal is to assess the safety and tolerability of Immunis’ investigational stem cell secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease contributing to age-related disability
Multi-active Biologics for Immune and Age-related Diseases - Immunis, Inc. Immunis developed a novel method to grow human cells for clinical use and direct them to become highly pure populations of defined cells that secrete hundreds of all-natural factors Our technology captures these powerful multi-active biologics to produce an investigational therapy called IMM01-STEM